Cost‐effectiveness of finerenone added to standard of care for patients with type 2 diabetes‐related chronic kidney disease in the United States

Documenti analoghi

• Diabetic kidney disease, biomarkers, and finerenone
  di: Ashish Verma, et al.
  Pubblicazione: (2026)
• The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease
  di: Johannes David Smeijer, et al.
  Pubblicazione: (2024)
• Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4
  di: Vikas S. Sridhar, et al.
  Pubblicazione: (2024)
• Impact of non‐alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi‐cohort longitudinal study
  di: Lijun Zhao, et al.
  Pubblicazione: (2024)
• Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines
  di: Kaitlin J. Mayne, et al.
  Pubblicazione: (2024)